In 1995, the gene was discovered by Yosef Shiloh[6] who named its product ATM since he found that its mutations are responsible for the disorder
ataxia–telangiectasia.[7] In 1998, the Shiloh and
Kastan laboratories independently showed that ATM is a protein kinase whose activity is enhanced by DNA damage.[8][9]
Introduction
Throughout the
cell cycle DNA is monitored for damage. Damages result from errors during
replication, by-products of metabolism, general toxic drugs or
ionizing radiation. The cell cycle has different
DNA damage checkpoints, which inhibit the next or maintain the current
cell cycle step. There are two main checkpoints, the G1/S and the G2/M, during the cell cycle, which preserve correct progression. ATM plays a role in cell cycle delay after DNA damage, especially after
double-strand breaks (DSBs).[10] ATM is recruited to sites of double strand breaks by DSB sensor proteins, such as the MRN complex. After being recruited, it phosphorylates
NBS1, along other DSB repair proteins. These modified mediator proteins then amplify the DNA damage signal, and transduce the signals to downstream effectors such as
CHK2 and
p53.
Structure
The ATM gene codes for a 350 kDa protein consisting of 3056 amino acids.[11] ATM belongs to the superfamily of
phosphatidylinositol 3-kinase-related kinases (PIKKs). The PIKK superfamily comprises six Ser/Thr-protein kinases that show a sequence similarity to
phosphatidylinositol 3-kinases (PI3Ks). This protein kinase family includes
ATR (ATM- and RAD3-related),
DNA-PKcs (DNA-dependent protein kinase catalytic subunit) and
mTOR (mammalian target of rapamycin). Characteristic for ATM are five domains. These are from N-terminus to C-terminus the
HEAT repeat domain, the FRAP-ATM-
TRRAP (FAT) domain, the kinase domain (KD), the PIKK-regulatory domain (PRD) and the FAT-C-terminal (FATC) domain. The HEAT repeats directly bind to the C-terminus of
NBS1. The FAT domain interacts with ATM's kinase domain to stabilize the C-terminus region of ATM itself. The KD domain resumes kinase activity, while the PRD and the FATC domain regulate it. The structure of ATM has been solved in several publications using
cryo-EM. In the inactive form, the protein forms a
homodimer. In the canonical pathway, ATM is activated by the MRN complex and
autophosphorylation, forming active monomers capable of phosphorylating several hundred downstream targets. In the non-canonical pathway, e.g. through simulation by oxidative stress, the dimer can be activated by the formation of
disulfide bonds.[12] The entire N-terminal domain together with the FAT domain are adopt an α-helical structure, which was initially predicted by sequence analysis. This α-helical structure forms a
tertiary structure, which has a curved, tubular shape present for example in the
Huntingtin protein, which also contains HEAT repeats. FATC is the C-terminal domain with a length of about 30 amino acids. It is highly conserved and consists of an
α-helix.[13]
Function
A complex of the three proteins
MRE11,
RAD50 and
NBS1 (
XRS2 in yeast), called the
MRN complex in humans, recruits ATM to
double strand breaks (DSBs) and holds the two ends together. ATM directly interacts with the
NBS1 subunit and phosphorylates the histone variant
H2AX on Ser139.[14] This phosphorylation generates binding sites for adaptor proteins with a
BRCT domain. These adaptor proteins then recruit different factors including the effector protein kinase
CHK2 and the tumor suppressor
p53. The ATM-mediated DNA damage response consists of a rapid and a delayed response. The effector kinase CHK2 is phosphorylated and thereby activated by ATM. Activated CHK2 phosphorylates phosphatase
CDC25A, which is degraded thereupon and can no longer dephosphorylate
CDK1-
cyclin B, resulting in cell-cycle arrest. If the DSB can not be repaired during this rapid response, ATM additionally phosphorylates
MDM2 and
p53 at Ser15.[9] p53 is also phosphorylated by the effector kinase CHK2. These phosphorylation events lead to stabilization and activation of p53 and subsequent transcription of numerous p53 target genes including CDK inhibitor
p21 which lead to long-term cell-cycle arrest or even apoptosis.[15]
The protein kinase ATM may also be involved in mitochondrial homeostasis, as a regulator of mitochondrial autophagy (mitophagy) whereby old, dysfunctional mitochondria are removed.[16] Increased ATM activity also occurs in viral infection where ATM is activated early during dengue virus infection as part of autophagy induction and ER stress response.[17]
Regulation
A functional
MRN complex is required for ATM activation after DSBs. The complex functions upstream of ATM in mammalian cells and induces conformational changes that facilitate an increase in the affinity of ATM towards its substrates, such as CHK2 and p53.[10]
Inactive ATM is present in the cells without DSBs as dimers or multimers. Upon DNA damage, ATM autophosphorylates on residue Ser1981. This phosphorylation provokes dissociation of ATM dimers, which is followed by the release of active ATM monomers.[18] Further autophosphorylation (of residues Ser367 and Ser1893) is required for normal activity of the ATM kinase. Activation of ATM by the
MRN complex is preceded by at least two steps, i.e. recruitment of ATM to DSB ends by the mediator of DNA damage checkpoint protein 1 (
MDC1) which binds to
MRE11, and the subsequent stimulation of kinase activity with the
NBS1 C-terminus.
The three domains FAT, PRD and FATC are all involved in regulating the activity of the KD kinase domain. The FAT domain interacts with ATM's KD domain to stabilize the C-terminus region of ATM itself. The FATC domain is critical for kinase activity and highly sensitive to mutagenesis. It mediates protein-protein interaction for example with the histone
acetyltransferase TIP60 (HIV-1 Tat interacting protein 60 kDa), which acetylates ATM on residue Lys3016. The acetylation occurs in the C-terminal half of the PRD domain and is required for ATM kinase activation and for its conversion into monomers. While deletion of the entire PRD domain abolishes the kinase activity of ATM, specific small deletions show no effect.[13]
People who carry a
heterozygous ATM mutation have increased risk of mainly
pancreatic cancer,
prostate cancer,
stomach cancer and
invasive ductal carcinoma of the breast.[19] Homozygous ATM mutation confers the disease
ataxia–telangiectasia (AT), a rare human disease characterized by cerebellar degeneration, extreme cellular sensitivity to radiation and a predisposition to cancer. All AT patients contain mutations in the ATM gene. Most other AT-like disorders are defective in genes encoding the
MRN protein complex. One feature of the ATM protein is its rapid increase in kinase activity immediately following double-strand break formation.[20][8] The phenotypic manifestation of AT is due to the broad range of substrates for the ATM kinase, involving DNA repair,
apoptosis, G1/S, intra-S checkpoint and G2/M checkpoints, gene regulation,
translationinitiation, and
telomere maintenance.[21] Therefore, a defect in ATM has severe consequences in repairing certain types of damage to DNA, and
cancer may result from improper repair. AT patients have an increased risk for breast cancer that has been ascribed to ATM's interaction and phosphorylation of
BRCA1 and its associated proteins following DNA damage.[22]
Somatic ATM mutations in sporadic cancers
Mutations in the ATM gene are found at relatively low frequencies in sporadic cancers. According to COSMIC, the Catalogue Of Somatic Mutations In Cancer, the frequencies with which heterozygous mutations in ATM are found in common cancers include 0.7% in 713 ovarian cancers, 0.9% in central nervous system cancers, 1.9% in 1,120 breast cancers, 2.1% in 847 kidney cancers, 4.6% in colon cancers, 7.2% among 1,040 lung cancers and 11.1% in 1790 hematopoietic and lymphoid tissue cancers.[23] Certain kinds of
leukemias and
lymphomas, including
mantle cell lymphoma,
T-ALL, atypical
B cell chronic lymphocytic leukemia, and
T-PLL are also associated with ATM defects.[24] A comprehensive literature search on ATM deficiency in pancreatic cancer, that captured 5,234 patients, estimated that the total prevalence of germline or somatic ATM mutations in pancreatic cancer was 6.4%.[25] ATM mutations may serve as predictive biomarkers of response for certain therapies, since preclinical studies have found that ATM deficiency can sensitise some cancer types to
ATR inhibition.[26][27][28][29]
Frequent epigenetic deficiencies of ATM in cancers
ATM is one of the DNA repair genes frequently
hypermethylated in its promoter region in various cancers (see table of such genes in
Cancer epigenetics). The promoter methylation of ATM causes reduced protein or
mRNA expression of ATM.
More than 73% of brain tumors were found to be methylated in the ATM gene promoter and there was strong inverse correlation between ATM promoter methylation and its protein expression (p < 0.001).[30]
The ATM gene promoter was observed to be hypermethylated in 53% of small (impalpable) breast cancers[31] and was hypermethylated in 78% of stage II or greater breast cancers with a highly significant correlation (P = 0.0006) between reduced ATM mRNA abundance and aberrant methylation of the ATM gene promoter.[32]
In non-small cell lung cancer (NSCLC), the ATM promoter methylation status of paired tumors and surrounding histologically uninvolved lung tissue was found to be 69% and 59%, respectively. However, in more advanced NSCLC the frequency of ATM promoter methylation was lower at 22%.[33] The finding of ATM promoter methylation in surrounding histologically uninvolved lung tissue suggests that ATM deficiency may be present early in a
field defect leading to progression to NSCLC.
In squamous cell carcinoma of the head and neck, 42% of tumors displayed ATM promoter methylation.[34]
DNA damage appears to be the primary underlying cause of cancer,[35] and deficiencies in DNA repair likely underlie many forms of cancer.[36] If DNA repair is deficient, DNA damage tends to accumulate. Such excess DNA damage may increase
mutational errors during
DNA replication due to error-prone
translesion synthesis. Excess DNA damage may also increase
epigenetic alterations due to errors during DNA repair.[37][38] Such mutations and epigenetic alterations may give rise to cancer. The frequent epigenetic deficiency of ATM in a number of cancers likely contributed to the progression of those cancers.
Meiosis
ATM functions during
meiotic prophase.[39] The wild-type ATM gene is expressed at a four-fold increased level in human
testes compared to
somatic cells (such as skin fibroblasts).[40] In both mice and humans, ATM deficiency results in female and male
infertility. Deficient ATM expression causes severe meiotic disruption during
prophase I.[41] In addition, impaired ATM-mediated DNA DSB repair has been identified as a likely cause of aging of mouse and human oocytes.[42] Expression of the ATM gene, as well as other key DSB repair genes, declines with age in mouse and human oocytes and this decline is paralleled by an increase of DSBs in primordial follicles.[42] These findings indicate that ATM-mediated homologous recombinational repair is a crucial function of meiosis.
Inhibitors
Several ATM kinase inhibitors are currently known, some of which are already in clinical trials.[43][44][45] One of the first discovered ATM inhibitors is
caffeine with an IC50 of 0.2 mM and only a low selectivity within the
PIKK family.[46][47]Wortmannin is an irreversible inhibitor of ATM with no selectivity over other related PIKK and PI3K kinases.[48] The most important group of inhibitors are compounds based on the 3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one scaffold. The first important representative is the inhibitor is
Dactolisib (NVP-BEZ235), which was first published by Novartis as a selective mTOR/PI3K inhibitor.[49] It was later shown to also inhibit other PIKK kinases such as ATM, DNA-PK and ATR.[50] Various optimisation efforts by AstraZeneca (AZD0156,
AZD1390), Merck (M4076) and Dimitrov et al. have led to highly active ATM inhibitors with greater potency.[51][52][53]
Interactions
Ataxia telangiectasia mutated has been shown to
interact with:
^Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. (June 1995). "A single ataxia telangiectasia gene with a product similar to PI-3 kinase". Science. 268 (5218): 1749–53.
Bibcode:
1995Sci...268.1749S.
doi:
10.1126/science.7792600.
PMID7792600.
^Huang X, Halicka HD, Darzynkiewicz Z (November 2004). "Detection of histone H2AX phosphorylation on Ser-139 as an indicator of DNA damage (DNA double-strand breaks)". Current Protocols in Cytometry. Chapter 7: Unit 7.27.
doi:
10.1002/0471142956.cy0727s30.
ISBN0-471-14295-6.
PMID18770804.
S2CID32281084.
^Kurz EU, Lees-Miller SP (2004). "DNA damage-induced activation of ATM and ATM-dependent signaling pathways". DNA Repair. 3 (8–9): 889–900.
doi:
10.1016/j.dnarep.2004.03.029.
PMID15279774.
^
abChen J (September 2000). "Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage". Cancer Research. 60 (18): 5037–9.
PMID11016625.
^Mehdipour P, Karami F, Javan F, Mehrazin M (August 2015). "Linking ATM Promoter Methylation to Cell Cycle Protein Expression in Brain Tumor Patients: Cellular Molecular Triangle Correlation in ATM Territory". Molecular Neurobiology. 52 (1): 293–302.
doi:
10.1007/s12035-014-8864-9.
PMID25159481.
S2CID35412479.
^Delmonico L, dos Santos Moreira A, Franco MF, Esteves EB, Scherrer L, Gallo CV, et al. (October 2015). "CDKN2A (p14(ARF)/p16(INK4a)) and ATM promoter methylation in patients with impalpable breast lesions". Human Pathology. 46 (10): 1540–7.
doi:
10.1016/j.humpath.2015.06.016.
PMID26255234.
^Bolt J, Vo QN, Kim WJ, McWhorter AJ, Thomson J, Hagensee ME, et al. (November 2005). "The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms". Oral Oncology. 41 (10): 1013–20.
doi:
10.1016/j.oraloncology.2005.06.003.
PMID16139561.
^Galetzka D, Weis E, Kohlschmidt N, Bitz O, Stein R, Haaf T (April 2007). "Expression of somatic DNA repair genes in human testes". Journal of Cellular Biochemistry. 100 (5): 1232–9.
doi:
10.1002/jcb.21113.
PMID17177185.
S2CID23743474.
^Barlow C, Liyanage M, Moens PB, Tarsounas M, Nagashima K, Brown K, et al. (October 1998). "Atm deficiency results in severe meiotic disruption as early as leptonema of prophase I". Development. 125 (20): 4007–17.
doi:
10.1242/dev.125.20.4007.
PMID9735362.
^Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B, et al. (June 2000). "Role for ATM in DNA damage-induced phosphorylation of BRCA1". Cancer Research. 60 (12): 3299–304.
PMID10866324.
^Cortez D, Wang Y, Qin J, Elledge SJ (November 1999). "Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks". Science. 286 (5442): 1162–6.
doi:
10.1126/science.286.5442.1162.
PMID10550055.
^Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, et al. (December 1998). "ATM associates with and phosphorylates p53: mapping the region of interaction". Nature Genetics. 20 (4): 398–400.
doi:
10.1038/3882.
PMID9843217.
S2CID23994762.
^Westphal CH, Schmaltz C, Rowan S, Elson A, Fisher DE, Leder P (May 1997). "Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints". Cancer Research. 57 (9): 1664–7.
PMID9135004.
^Bao S, Tibbetts RS, Brumbaugh KM, Fang Y, Richardson DA, Ali A, et al. (June 2001). "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses". Nature. 411 (6840): 969–74.
Bibcode:
2001Natur.411..969B.
doi:
10.1038/35082110.
PMID11418864.
S2CID4429058.
Kurz EU, Lees-Miller SP (2005). "DNA damage-induced activation of ATM and ATM-dependent signaling pathways". DNA Repair. 3 (8–9): 889–900.
doi:
10.1016/j.dnarep.2004.03.029.
PMID15279774.
Abraham RT (2005). "The ATM-related kinase, hSMG-1, bridges genome and RNA surveillance pathways". DNA Repair. 3 (8–9): 919–25.
doi:
10.1016/j.dnarep.2004.04.003.
PMID15279777.
Lavin MF, Scott S, Gueven N, Kozlov S, Peng C, Chen P (2005). "Functional consequences of sequence alterations in the ATM gene". DNA Repair. 3 (8–9): 1197–205.
doi:
10.1016/j.dnarep.2004.03.011.
PMID15279808.